Wow. Very disappointed in "The Street". They're talking about revenue going down like it's a drop in sales activities. There are no sales! All revenues came from development deals and it was as clear as day a couple of year ago that they would be going down. So, how come they didn't downgrade it then.
It's OK to downgrade it if you don't believe in their product pipeline. Also, I have noted my concern that we're not really going to see much news about clinical trials that are under Abbott's control, but with the splitting up of Abbott, Abvie is going to have to provide more about pipeline stories, so we will hear more then we would have before the split.
I guess that's why we have been going down. At least we know that it's nothing based on real news or new bad facts. It's just someone trying to use their financial modeling tools on a biotech company. Good luck with that.
Agreed - this is a development stage biotech. Anyone knows ratings should be based on pipeline prospects, not p/e. It may be that those prospects are getting so close that other forces have decided it's time to accumulate and The Street is not exactly what could be termed a reputable player in this regard. Buy on the dips here. That's my plan.
Kitty, I only have a little SNTS now, but I read the conference call transcripts. Things are going really well there. I did really well with that one. I bought some AMSC and got clobbered with that one. I guess I should stick to biotech stocks, but overall things are good.
NBIX will be a good one. I have a big position here now. As we get closer to Elagolix results, the stock will move up nicely. I can't tell what AbVie (Abbott spinoff) will do for news on this. If they stay quiet, it could be another three months or even a little more before we see a rally. So, it may require a lot of patience. Who knows. Anyway, this one, like SNTS when it was at $3 a share, will have it's day. Of course, there's no big court trial to win here, like SNTS had. Best of luck.